3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Prostatic Neoplasms
1
Neoplasms by Histologic Type
1
Neoplasms
1
Neoplasm Metastasis
1
NSCLC
1
Myeloproliferative Disorders
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia
1
Hematologic Diseases
1
Granulosa Cell Tumor
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Bone Marrow Diseases
1
Advanced Solid Tumor
1
Interventions
Injections
3
pembrolizumab
2
olaparib
2
atezolizumab
2
Leucovorin
2
Irinotecan
2
ulixertinib
1
toripalimab
1
tipifarnib
1
sotorasib
1
serabelisib
1
mirdametinib
1
famitinib
1
camrelizumab
1
adagrasib
1
Taxes
1
Ramucirumab
1
Radiation
1
Paclitaxel
1
IFL protocol
1
Granulocyte Colony-Stimulating Factor
1
Gemcitabine
1
Fluorouracil
1
Docetaxel
1
Bevacizumab
1
BID protein, human
1
Appointments and Schedules
1
Albumin-Bound Paclitaxel
1
APG-1387
1
5-fluorouridine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Advanced Solid Tumor
×
BID protein, human
×
Clear all
NCT06560632
2026-01-16
POLAR
Repare Therapeutics
Phase 1
Terminated
26 enrolled
14 charts